61 related articles for article (PubMed ID: 11007262)
1. Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone.
Cuccorese G; Tursi A; Spinazzola AM; Modeo ME; Miglietta A
Am J Gastroenterol; 2000 Sep; 95(9):2399-400. PubMed ID: 11007262
[No Abstract] [Full Text] [Related]
2. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
[TBL] [Abstract][Full Text] [Related]
3. [Two-step interferon rebound therapy].
Kato M; Yuki N; Iyoda K; Yamamoto K; Hayashi N
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):497-501. PubMed ID: 15359849
[No Abstract] [Full Text] [Related]
4. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.
Davis GL
Semin Liver Dis; 1999; 19 Suppl 1():49-55. PubMed ID: 10349692
[TBL] [Abstract][Full Text] [Related]
5. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
[TBL] [Abstract][Full Text] [Related]
6. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
Asahina Y; Izumi N
Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
[No Abstract] [Full Text] [Related]
7. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
8. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
[TBL] [Abstract][Full Text] [Related]
9. Interferon alpha plus ketoprofen or interferon alpha plus ribavirin in chronic hepatitis C non-responder to interferon alpha alone: results of a pilot study.
Andreone P; Cursaro C; Gramenzi A; Fiorino S; Di Giammarino L; Miniero R; D'Errico A; Grigioni WF; Gasbarrini G; Bernardi M
Ital J Gastroenterol Hepatol; 1999 Nov; 31(8):688-94. PubMed ID: 10730561
[TBL] [Abstract][Full Text] [Related]
10. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
[TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
Hoofnagle JH; Ghany MG; Kleiner DE; Doo E; Heller T; Promrat K; Ong J; Khokhar F; Soza A; Herion D; Park Y; Everhart JE; Liang TJ
Hepatology; 2003 Jul; 38(1):66-74. PubMed ID: 12829988
[TBL] [Abstract][Full Text] [Related]
12. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
13. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
14. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
Puoti C; Bellis L; Castellacci R; Montagnese F
Hepatology; 2005 Mar; 41(3):683; author reply 684. PubMed ID: 15723301
[No Abstract] [Full Text] [Related]
15. [Experience in complex therapy ribavine chronic viral hepatitis C].
Domashenko OM
Lik Sprava; 2011; (3-4):101-3. PubMed ID: 22416372
[TBL] [Abstract][Full Text] [Related]
16. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
[TBL] [Abstract][Full Text] [Related]
17. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
[TBL] [Abstract][Full Text] [Related]
19. Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone.
Milella M; Santantonio T; Pietromatera G; Maselli R; Casalino C; Mariano N; Genchi C; Pastore G
Ital J Gastroenterol Hepatol; 1999 Apr; 31(3):211-5. PubMed ID: 10379482
[TBL] [Abstract][Full Text] [Related]
20. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
Brillanti S; Levantesi F; Masi L; Foli M; Bolondi L
Hepatology; 2000 Sep; 32(3):630-4. PubMed ID: 10960460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
